Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee
Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lo...
| Main Authors: | , |
|---|---|
| Published: |
Digital Commons @ East Tennessee State University
2012
|
| Subjects: | |
| Online Access: | https://dc.etsu.edu/etsu-works/2357 |
| Summary: | Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%. |
|---|